• Investors may be wondering whether DaVita's share price still offers value after a strong run, or if most of the opportunity has already been priced in.
• The stock closed at US$194.61, with returns of 31.6% over the past month, 70.0% year to date and 33.5% over the past year. This naturally raises questions about growth potential and changes in perceived risk.
• Recent attention on DaVita has focused on how investors view the resilience of its dialysis business model and the long term demand for kidney care services. This backdrop helps explain why the stock's stronger recent returns are firmly on the radar for many healthcare focused investors.
• On Simply Wall St's valuation checks, DaVita records a value score of 3 out of 6. The rest of this article will walk through how different valuation approaches line up for the stock and will introduce an additional way to think about valuation at the end.

Approach 1: DaVita Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and discounting them back to today’s value using a required return. It focuses on the cash that may be available to shareholders, not accounting earnings.

For DaVita, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $1.44b. Simply Wall St shows forecast Free Cash Flow of $1.03b in 2026, then extends those projections further out to 2035 using its own assumptions, with discounted figures ranging from about $950.47m in 2026 to $221.41m in 2035. All of these cash flows are expressed in $.

When those projected cash flows are added up and discounted, the estimated intrinsic value comes out at about $142.63 per share. Compared with the recent share price of $194.61, this represents a difference of around 36.4% above the DCF estimate within this model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DaVita may be overvalued by 36.4%. Discover 54 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: DaVita Price vs Earnings

For a profitable company like DaVita, the P/E ratio is a useful way to think about value because it links what you pay directly to the earnings the business is generating today. Investors generally accept that higher growth potential and lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty tend to support a lower, more cautious multiple.

DaVita currently trades on a P/E of about 16.5x. That sits below the Healthcare industry average of roughly 23.3x and also below the peer group average of about 33.3x, which may catch your eye if you are comparing stocks within the sector.

Simply Wall St’s Fair Ratio for DaVita is 25.3x. This is a proprietary estimate of what the P/E might be, given factors such as earnings growth, profit margins, market cap, risks and the company’s industry. Because it adjusts for these company specific characteristics, it can offer a more tailored reference point than simply lining the stock up against broad industry or peer averages.

With the current P/E of 16.5x sitting below the Fair Ratio of 25.3x, this approach suggests the stock is trading below that company specific reference level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your DaVita Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about DaVita, such as how its dialysis and Integrated Kidney Care businesses handle GLP 1 headwinds, technology spending or reimbursement risk, and connect that story directly to a set of revenue, earnings and margin forecasts. These forecasts roll up into a Fair Value that you can compare with today’s price to help you decide whether to act. All of this is available inside Simply Wall St’s Community page, where Narratives are updated automatically when fresh news or earnings land. You might see one investor lean toward the higher Fair Value implied by the most bullish analyst target of US$235, while another leans toward the lower Fair Value suggested by the most cautious US$145 view, with each Narrative clearly spelling out the assumptions behind those very different stances.

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.